From Vision to Reality
Starting with colorectal cancer, we plan to change the process according to which cancer patients are treated. We will do so by introducing functional drug sensitivity testing as the standard of care when decisions are made as to treatment.
Greater treatment impact will reduce the vast sums of money spent each year on treatments that are either not optimal, simply ineffective or have unnecessary side-effects. We are talking about hundreds of millions of euros each year.
We aim to address multiple types of cancer. But the market for testing in colorectal cancer alone is estimated at over 1 billion Euros. As first entrant our aim is to gain a significant share of this potential.
Please click on each section for more details.
Our vision is that functional drug sensitivity testing becomes routine – alongside other diagnostic approaches such as genomics and proteomics - for every cancer patient before any treatment decisions are made, so that personalised medicine finally becomes truly personal.
A paradigmatic example is the indiscriminate use of antibiotics in the past, which gave way to resistances and the appearance of “superbugs” (strains of bacteria, viruses, parasites and fungi that are resistant to most of the antibiotics and other medications commonly used). Billions are wasted on non-helpful therapies. Why use chemotherapy that is not going to work? Why waste already scare resources? Functional drug sensitivity testing can help.
With the processes, people and expertise described in this Market Approach, we believe we have the necessary pieces in place to take the leading role in this shift, and so to change the way therapy decisions are made for the benefit of patients, healthcare professionals and the healthcare system as a whole.